全文获取类型
收费全文 | 503篇 |
免费 | 15篇 |
国内免费 | 1篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 17篇 |
基础医学 | 48篇 |
口腔科学 | 10篇 |
临床医学 | 23篇 |
内科学 | 104篇 |
神经病学 | 51篇 |
特种医学 | 8篇 |
外科学 | 115篇 |
预防医学 | 4篇 |
眼科学 | 8篇 |
药学 | 14篇 |
肿瘤学 | 115篇 |
出版年
2024年 | 1篇 |
2022年 | 5篇 |
2021年 | 4篇 |
2020年 | 5篇 |
2019年 | 3篇 |
2018年 | 14篇 |
2017年 | 7篇 |
2016年 | 11篇 |
2015年 | 11篇 |
2014年 | 18篇 |
2013年 | 21篇 |
2012年 | 32篇 |
2011年 | 43篇 |
2010年 | 34篇 |
2009年 | 19篇 |
2008年 | 21篇 |
2007年 | 40篇 |
2006年 | 36篇 |
2005年 | 33篇 |
2004年 | 22篇 |
2003年 | 27篇 |
2002年 | 27篇 |
2001年 | 8篇 |
2000年 | 6篇 |
1999年 | 4篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 4篇 |
1995年 | 6篇 |
1994年 | 8篇 |
1993年 | 5篇 |
1992年 | 1篇 |
1991年 | 4篇 |
1990年 | 5篇 |
1989年 | 3篇 |
1988年 | 3篇 |
1986年 | 2篇 |
1983年 | 1篇 |
1981年 | 3篇 |
1980年 | 1篇 |
1979年 | 2篇 |
1978年 | 3篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 6篇 |
1973年 | 2篇 |
1958年 | 1篇 |
排序方式: 共有519条查询结果,搜索用时 125 毫秒
1.
2.
Antitumor Immunity Induction by Intracellular Hyperthermia Using Magnetite Cationic Liposomes 总被引:10,自引:0,他引:10
Mitsugu Yanase Masashige Shinkai Hiroyuki Honda Toshihiko Wakabayashi Jun Yoshida Takeshi Kobayashi 《Cancer science》1998,89(7):775-782
Induction of antitumor immunity to T-9 rat glioma by intracellular hyperthermia using functional magnetic particles was investigated. Magnetite cationic liposomes (MCLs), which have a positive surface charge, were used as heating mediators for intracellular hyperthermia. Solid T-9 glioma tissues were formed subcutaneously on both femurs of female F344 rats, and MCLs were injected via a needle only into the left solid tumors (treatment side). The rats were then divided into two groups, which received no irradiation, or irradiation for 30 min given three times at 24-h intervals with an alternating magnetic field (118 kHz, 384 Oe). On the treatment side, the tumor tissue disappeared completely in many rats exposed to the magnetic field. The tumor tissue on the opposite side also disappeared completely, even though MCLs were not injected into the right solid tumors. To examine whether a long-lasting and tumor-specific immunity could be generated, the rats that had been cured by the hyperthermia treatment were rechallenged with T-9 cells 3 months later. After a period of transient growth, all tumors disappeared. Furthermore, immuno-cytochemical assay revealed that the immune response induced by the hyperthermia treatment was mediated by both CD8+ and CD4+ T cells and accompanied by a marked augmentation of tumor-selective cytotoxic T lymphocyte activity. These results suggest that our magnetic particles are potentially effective tools for hyperthermic treatment of solid tumors, because in addition to killing of the tumor cells by heat, a host immune response is induced. 相似文献
3.
Shin-ichi Fukumoto Naoko Yamauchi Hisashi Moriguchi Yoshitaka Hippo Akira Watanabe Junji Shibahara Hirokazu Taniguchi Shumpei Ishikawa Hirotaka Ito Shogo Yamamoto Hiroko Iwanari Mitsugu Hironaka Yuichi Ishikawa Toshiro Niki Yasunori Sohara Tatsuhiko Kodama Masaharu Nishimura Masashi Fukayama Hirotoshi Dosaka-Akita Hiroyuki Aburatani 《Clinical cancer research》2005,11(5):1776-1785
PURPOSE: Squamous cell carcinoma (SCC) and adenocarcinoma of the lung are currently subject to similar treatment regimens despite distinct differences in histology and epidemiology. The aim of this study is to identify a molecular target with diagnostic and therapeutic values for SCC. EXPERIMENTAL DESIGN: Genes specifically up-regulated in SCC were explored through microarray analysis of 5 SCCs, 5 adenocarcinomas, 10 small cell lung carcinomas, 27 normal tissues, and 40 cancer cell lines. Clinical usefulness of these genes was subsequently examined mainly by immunohistochemical analysis. RESULTS: Seven genes, including aldo-keto reductase family 1, member B10 (AKR1B10), were identified as SCC-specific genes. AKR1B10 was further examined by immunohistochemical analysis of 101 non-small cell lung carcinomas (NSCLC) and its overexpression was observed in 27 of 32 (84.4%) SCCs and 19 of 65 (29.2%) adenocarcinomas. Multiple regression analysis showed that smoking was an independent variable responsible for AKR1B10 overexpression in NSCLCs (P < 0.01) and adenocarcinomas (P < 0.01). AKR1B10 staining was occasionally observed even in squamous metaplasia, a precancerous lesion of SCC. CONCLUSION: AKR1B10 was overexpressed in most cases with SCC, which is closely associated with smoking, and many adenocarcinoma cases of smokers. These results suggest that AKR1B10 is a potential diagnostic marker specific to smokers' NSCLCs and might be involved in tobacco-related carcinogenesis. 相似文献
4.
Motohiro Hirao Hideyasu Omiya Koji Takami Kazuyoshi Yamamoto Kazuhiro Nishikawa Masataka Ikeda Atsushi Miyamoto Naoki Hama Masakazu Miyake Mamoru Uemura Sakae Maeda Shoji Nakamori Mitsugu Sekimoto 《Esophagus》2016,13(2):163-166
Background and objective
Pulmonary metastasectomy is a standard therapy for some types of metastatic lesions in the lung. Although the prognosis for esophageal cancer patients with pulmonary metastasis is poor, it has been reported that some post-esophagectomy patients have good prognosis after pulmonary metastasectomy. We investigated the role of resecting pulmonary metastases arising from esophageal cancer at our institution.Patients and methods
Seven patients with primary squamous cell carcinoma or adenocarcinoma of the thoracic esophagus who underwent resection of metachronous pulmonary metastases at our institution between 2006 and 2012 were identified from a retrospective database. All patients had undergone curative resection of their primary esophageal carcinoma.Results
Six patients had unilateral and solitary lung metastasis. One patient presented with one metastatic lesion on each side, and he underwent 4 metastasectomy for pulmonary metastasis 3 times. There was no perioperative morbidity or mortality. The disease-free interval after esophagectomy ranged from 191 to 559 days (median, 463 days). Survival after pulmonary metastasectomy ranged from 357 to 3191 days (median, 1803 days). Three patients received systemic chemotherapy before metastasectomy. Currently, 5 patients are alive without evidence of recurrent disease.Conclusion
Pulmonary metastasectomy may be acceptable as a part of multimodal treatment for solitary metachronous pulmonary metastasis in esophageal carcinoma.5.
Takahiro Hayashi Masaru Miyataka Akio Kimura Mitsugu Taniguchi Atsuhiro Kurooka Hiroshi Yabushita Takashi Kiyoshima Hajime Nakamura Yutaka Hirano Kinji Ishikawa 《Circulation journal》2005,69(4):420-426
BACKGROUND: Many patients with acute myocardial infarction will still die after admission. Recent trends in hospital mortality were analyzed to identify aspects that need improvement. METHODS AND RESULTS: A total of 1,247 patients admitted to Kinki University School of Medicine within 24 h of the onset of infarction were analyzed between 1975 and 2001. The percentage of patients discharged with 100% occlusion decreased gradually from 31.3% during 1975-1982 to 2.1% during 1998-2001, while those with 50% stenosis or less gradually increased from 12.5% to 82.5% during the same period (trends: p < 0.01). The cardiac death rate was 17.1% in 1975-1982, and 7.7% in 1998-2001, showing a significant decrease with time (p < 0.01). This decrease was particularly marked among those admitted within 6 h of the onset of infarction. Death due to cardiac rupture decreased significantly with time (p < 0.001). In contrast, the non-cardiac death rate, amounting to 2.2% on average, did not decline. CONCLUSIONS: Cardiac deaths due to acute myocardial infarction have decreased markedly of late. However, patients must be admitted within 6 h of the onset of infarction to benefit from this improvement. More effort should be made to improve the general care of patients in order to reduce the incidence of non-cardiac death. 相似文献
6.
7.
Yukinori Nakagawa Uichi Ikeda Masahiro Hirose Satoshi Ubukata Taka-Aki Katsuki Yuichiro Kaminishi Tsutomu Saito Mitsugu Hironaka Tohru Izumi Kazuyuki Shimada 《Circulation journal》2004,68(2):172-173
Primary cardiac malignant lymphoma is extremely rare and almost all patients die within weeks. Monoclonal CD20 antibody (rituximab) was administered to a patient with primary cardiac B-cell non-Hodgkin's lymphoma expressing a CD20 molecule. The results suggest that rituximab may be a safe and effective new therapy for primary cardiac B-cell lymphoma. 相似文献
8.
9.
A case of repetitive intrapleural cancer chemotherapy using INFUSE-A-PORT for malignant mesothelioma
Omasa M Hirata T Shoji T Bando T Hasegawa S Inui K Wada H 《The Thoracic and cardiovascular surgeon》2001,49(4):233-235
A 57-year-old man was diagnosed as having malignant pleural mesothelioma. We placed an implantable reservoir (INFUSE-A-PORT) into his pleural cavity to administer repetitive intrapleural chemotherapy. We administered intrapleural chemotherapy 7 times over a period of 10 months. The progression of the disease was very gradual; he could continue working during this time. INFUSE-A-PORT may be useful for repetitive intrapleural chemotherapy in outpatient treatment of malignant mesothelioma. 相似文献
10.